MapLight Therapeutics
MPLT----
MapLight Therapeutics (MPLT)
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. Th...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
MapLight Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$35.77261.12%
Forecast & RatingStrong buy
14analysts
- Strong buy85.71%
- Buy7.14%
- Hold7.14%
- Sell0.00%
- Strong sell0.00%
News
- US Stock Market Update · 6 hours ago
MapLight Therapeutics plunges 71% as schizophrenia drug fails dosing test
- US Stock Market Update · 8 hours ago
MapLight Therapeutics plunges 68% as once-daily dosing test fails
- benzinga_article · 9 hours ago
12 Health Care Stocks Moving In Monday's Intraday Session
- US Stock Market Update · 12 hours ago
MapLight Therapeutics plunges 62% as drug fails once-daily dosing test
- benzinga_article · 14 hours ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
- PUBT · 15 hours ago
MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophrenia
